Kailera Therapeutics, Inc. reported results
SEC 8-KRead source ↗
Kailera Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders5 buying, 0 selling5 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds96 adding, 0 cuttingOf 25 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 49% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Kailera Therapeutics, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 72% and a beta of 1.2 against the S&P 500.
- Short interest rising. Shares sold short rose 39% in a month to 6.4% of tradable shares.
Latest results
- Earnings per share
- -$1.09 against an average estimate of -$0.73: missed by 49.4%
- Share reaction
- -4.8% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
- Next report
- November 4, 2026; average EPS estimate -$1.01
Price chart
- 1 day+3.5%
- 1 week-4.3%
- 1 month+21.0%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 12, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
No model value for Kailera Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Kailera Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kailera Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 4, 2026, after the close. Analysts expect revenue of $0 and EPS of −$1.01 (range −$1.30 to −$0.79) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$4.10 | — | — | — |
| Next | −$4.30 | −5% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +3.2% on 90 days ago. In the last 30 days, 0 analysts raised Kailera Therapeutics, Inc.'s forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$3.97 | −$4.10 |
| 60 days ago | −$3.97 | −$4.10 |
| 30 days ago | −$4.38 | −$4.30 |
| 7 days ago | −$4.10 | −$4.30 |
| Now | −$4.10 | −$4.30 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.73 | −$1.09 | −49.4% |
| Mar 2026 | −$0.55 | −$3.65 | −565.1% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 6.4% of tradable shares
- Days to cover
- 5.58 at average volume
- Short interest, 1 month
- +39% to October 15, 2026
- Held by institutions
- 91% of shares
- Held by insiders
- 8.9% of shares
- Employees
- 145 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −7.9%
- vs 200-day average
- —
- Volatility (1 year)
- 72%
- Beta vs S&P 500
- 1.21
Share price after results
- Next day
- 1 up, 1 down typical move ±4.2%
- After a week
- 1 up, 1 down typical move ±4.8%
- After a month
- 0 up, 2 down typical move ±14.2%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 12, 2026 | −4.8% | +0.9% | −2.9% | −26.1% |
| May 26, 2026 | +3.5% | +0.6% | +6.7% | −2.4% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $2.6B
- Institutions reporting
- 99
- Positions opened / closed
- 96 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Bain Capital Investors LLC | $578M | 26.3M | 22.6% | — |
| Bain Capital Life Sciences Investors, LLC | $498M | 22.6M | 19.4% | — |
| RTW Investments, LP | $237M | 10.8M | 9.3% | — |
| Canada Pension Plan Investment Board | $161M | 7.3M | 6.3% | — |
| Atlas Venture Life Science Advisors, LLC | $114M | 5.2M | 4.5% | — |
| FMR LLC | $87.5M | 4.0M | 3.4% | — |
| Blackrock, Inc. | $86.5M | 3.9M | 3.4% | — |
| Price T Rowe Associates Inc | $77.9M | 3.5M | 3.0% | — |
| Citadel Advisors LLC | $71.4M | 3.2M | 2.8% | — |
| Adage Capital Partners Gp, L.L.C. | $70.7M | 3.2M | 2.8% | — |
| Wellington Management Group LLP | $64.3M | 2.9M | 2.5% | — |
| Royalty Pharma Sub-Manager, LLC | $54.1M | 2.5M | 2.1% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kailera Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $327M 5 trades by 5 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $327M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Kaplan Andrew T. Director | April 20, 2026 | Buy | 8,398,438 | $16.00 | $134M |
| Bcls Fund Iv Investments Gp, Llc 10% owner | April 20, 2026 | Buy | 1,562,500 | $16.00 | $25M |
| Koppel Adam Director | April 20, 2026 | Buy | 1,562,500 | $16.00 | $25M |
| Bcpe Perseus Investor, Lp 10% owner | April 20, 2026 | Buy | 8,398,438 | $16.00 | $134M |
| Rtw Investments, Lp 10% owner | April 20, 2026 | Buy | 500,000 | $16.00 | $8M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 12, 2026
- May 26, 2026
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- S-1 S-1
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Kailera Therapeutics, Inc. in brief
- What does Kailera Therapeutics, Inc. do?
- Kailera Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Kailera Therapeutics, Inc.'s stock ticker?
- Kailera Therapeutics, Inc. trades under the ticker KLRA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Kailera Therapeutics, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Bain Capital Investors LLC, Bain Capital Life Sciences Investors, LLC and RTW Investments, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Kailera Therapeutics, Inc. stock?
- Over the last 12 months, Kailera Therapeutics, Inc.'s directors and officers reported 5 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Kailera Therapeutics, Inc.'s next earnings date?
- Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kailera Therapeutics, Inc. announces its own schedule.
Follow research on Kailera Therapeutics, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.